It has been demonstrated that irisin acts as a protective factor and a potential biomarker for obesity-related comorbidities, while alterations in myonectin and myostatin further contribute to cardiometabolic risk in MASLD patients [91,92]. Here, FNDC5 is linked to obesity disorder.